Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma

Inclusion Criteria: * Confirmed diagnosis of follicular lymphoma, according to the Revised European American Lymphoma/World Health Organization \[REAL/WHO\] classification * Documented CD40+ follicular lymphoma * Measurable lesion * Refractory to rituximab * Prior treatment with at least 1 chemotherapeutic regimen * 18 years or older * WHO Performance Status grade 0, 1, or 2 * Life expectancy \> 3 months * Obtained written informed consent Exclusion Criteria: * Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma (i.e. DLBCL) * History of another primary malignancy that is currently clinically significant or currently requires active intervention * Prior allogeneic stem cell transplantation * Prior anaphylactic or other severe infusion reaction such that the patient is unable to tolerate human immunoglobulin or monoclonal antibody administration * Impaired cardiac function or clinically significant cardiac disease * History of acute or chronic pancreatitis, surgery of the pancreas, or any risk factors that may increase the risk of pancreatitis * History of an active infection (viral, bacterial, or fungal) requiring systemic therapy within 28 days before study treatment. * Known diagnosis of human immunodeficiency virus (HIV) infection * Evidence of previous hepatitis viral infection such as hepatitis B or hepatitis C * Ongoing corticosteroid use (\>10 mg/day prednisone or equivalent) * Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion criteria may apply